RET and medullary thyroid gland carcinoma: The latest AFIRMA Genomic Sequencing Classifier is based on RNA sequencing and analysis of BRAFV600E mutations, RET/PTC1 or RET/PTC3, and specific alterations characteristic of parathyroid lesions, medullary thyroid cancer, and Hürtle cell lesions.